Skip to main content
OpenTrials
Completed

NCT Number: NCT00274235

Intermittent Preventive Treatment During Pregnancy in Benin

Malaria in pregnancy is one of the most important preventable causes of low birthweight worlwide and a major cause of severe maternal anaemia contributing to maternal mortality. Intermittent Preventive Treatment (IPT) with sulfadoxine-pyrimethamine (SP) is the currently adopted government recommendation for malaria control during pregnancy in Benin, but the emergence and the spread of resistance to SP justifies the evaluation of alternative anti-malarial drugs. Mefloquine (MQ), which has been proven effective and reasonably safe in this indication, may be an interesting alternative to SP. The aim of this trial is to compare the efficacy and safety of sulfadoxine-pyrimethamine and mefloquine for IPT. It is an equivalent study designed to test the hypothesis that MQ is as efficacious as SP to prevent malaria in pregnancy, and that it could replace SP when resistance of Plasmodium falciparum becomes too elevated. Primary endpoint will be the proportion of infants with low birthweight. Secondary endpoints will be the proportion of mothers with placental plasmodial infection, and the proportion of mothers with anaemia at delivery.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Malaria Anemia Hematologic Diseases Hemic and Lymphatic Diseases Infections Mosquito-Borne Diseases Parasitic Diseases Protozoan Infections Vector Borne Diseases

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Institut de Recherche pour le Développement

Cotonou, 01 BP 4414 RP, Benin

About this study

The trial will be conducted in two maternity clinics in Ouidah, 40km from Cotonou. A total of 1600 women will be selected and randomised to receive either SP (1500 mg sulfadoxine with 75 mg pyrimethamine) or MQ (15 mg/kg) twice during pregnancy at ante-natal clinic (ANC) visits. The first dose will be given between 16 and 28 weeks of gestation, the second between 30 and 36 weeks, and at least one month after the first dose. Women will be visited at home within one week after the initial and subsequent ANC visits to check for adverse reactions due to the study drugs. Peripheral blood samples will be collected on each ANC visit to assess for haemoglobin level and parasitemia. Peripheral, placental, and cord blood samples will be collected at delivery for haematological determinations and parasitological examination. Birthweight will be recorded and the gestational age assessed by the Ballard method. The mother and her child will be assessed for general health status six weeks after birth.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnancy between 16 and 28 weeks of gestation
  • Residence near the maternity clinics
  • Intention to continue the ante-natal care and deliver at the study maternity clinic
  • Ability to take drugs by oral route
  • Written informed consent (parents or guardian if aged < 18 years)

Exclusion criteria

  • Pregnancy prior to 16 weeks or after 28 weeks of gestation
  • Previous suspected reaction to sulfadoxine-pyrimethamine or mefloquine
  • History of neurological or psychiatric event
  • Intake of sulfadoxine-pyrimethamine or mefloquine within 4 weeks of enrollment
  • Current treatment with halofantrine

Treatment and study plan

sulfadoxine-pyrimethamine / mefloquine

Drug

Primary outcomes

  1. proportion of infants with low birthweight (<2,500 grams)

Secondary outcomes

  1. mean birthweight

  2. proportion of mothers with placental plasmodial infection

  3. proportion of preterm deliveries

  4. proportion of mothers with anaemia (Haemoglobin level (Hb)<11g/dl) and severe anaemia (Hb<8g/dl) at delivery

  5. proportion of mothers with parasitaemia at delivery

  6. proportion of adverse events after taking study drugs

  7. proportion of congenital abnormalities

  8. proportion of stillbirths

Sponsors and collaborators

Lead sponsor

Institut de Recherche pour le Developpement

Other Gov

Collaborators

  • Faculté des Sciences de la Santé, Bénin
  • Institut des Sciences Biomédicales Appliquées, Bénin
  • Ministry of Foreign Affairs, France
  • National Malaria Control Program, Benin

Registry information

Official study title

Intermittent Preventive Treatment During Pregnancy in Benin: a Randomized, Open, and Equivalent Trial Comparing Sulfadoxine-Pyrimethamine With Mefloquine

Important dates

Study start
2005
Primary completion
2008
Study completion
2008
First posted
Jan 10, 2006
Registry last updated
Oct 31, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.